These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9129688)

  • 1. Antigen-specific agents in development.
    Sznol M; Holmlund J
    Semin Oncol; 1997 Apr; 24(2):173-86. PubMed ID: 9129688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.
    Krueger P; Nitz C; Foster R; MacDonald C; Gelber O; Lalehzadeh G; Goodson R; Winter J; Gelber C
    Cancer Immunol Immunother; 2003 Jun; 52(6):367-77. PubMed ID: 12669243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolution of antibodies into versatile tumor-targeting agents.
    Lin MZ; Teitell MA; Schiller GJ
    Clin Cancer Res; 2005 Jan; 11(1):129-38. PubMed ID: 15671537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity.
    Kennedy RC; Shearer MH; Lowe DB; Jumper CA; Chiriva-Internati M; Bright RK
    Cancer Immunol Immunother; 2004 Nov; 53(11):987-94. PubMed ID: 15156293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA tumor vaccines.
    Wlazlo AP; Ertl HC
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):1-11. PubMed ID: 11266084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccines, a critical review--Part II.
    Mitchell MS
    Curr Opin Investig Drugs; 2002 Jan; 3(1):150-8. PubMed ID: 12054066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
    Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
    Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible applications of antibodies or their genes in cancer therapy.
    Kuroki M; Huang J; Shibaguchi H; Tanaka T; Zhao J; Luo N; Hachimine K; Kinugasa T; Maekawa S; Enatsu S; Hamanaka W; Fukami T; Kuroki M
    Anticancer Res; 2006; 26(6A):4019-25. PubMed ID: 17195452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
    Savelyeva N; King CA; Vitetta ES; Stevenson FK
    Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies and vaccines--hope or illusion?
    Jäger D; Knuth A
    Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current status and prospects for targeted therapy for thyroid cancer].
    Shimizu K; Mimura T; Harada T; Tanaka S
    Gan To Kagaku Ryoho; 1994 May; 21(6):743-8. PubMed ID: 8185329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.